A Phase I/II Study of Chemoradiation With Oxaliplatin and 5FU for Locally Advanced Pancreatic Cancer
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 入组人数
- 24
- 试验地点
- 2
- 主要终点
- Resectability After Chemoradiation
研究概览
简要总结
The intention of this trial is to determine the maximum tolerated of the treatment combination and to evaluate its safety and efficacy.
详细描述
Previous studies have demonstrated that neoadjuvant chemoradiation can lead to improved survival with a portion of patients proceeding to resection. This trial will incorporate a similar trial structure using newer agents in patients who present with locally advanced unresectable pancreatic cancer. Specifically oxaliplatin will be used owing to its greater activity in comparison to cisplatin and favorable therapeutic index in combination with radiation compared to gemcitabine.
In summary, the primary outcome measure of the phase I portion of the trial is to determine the maximum tolerated dose of this combination. Following the determination of this dose, the phase II portion of the trial will characterize the toxicity of this regimen as well as evaluate for long-term efficacy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Pathologically documented pancreatic adenocarcinoma deemed unresectable due to local involvement of vessels or organs
- •Patients with a clear clinical diagnosis of localized pancreatic cancer deemed unresectable, who have undergone at least 2 biopsies which were not diagnostic of adenocarcinoma, may be entered at the discretion of the principal investigator.
- •No prior chemotherapy or abdominal radiation therapy.
- •Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1
- •Clinically measurable or evaluable disease.
- •Life expectancy of at least 12 weeks.
- •Adequate bone marrow reserve, granulocyte count >= 1500/uL, platelet count >= 100,000/uL, hemoglobin >= 9 g/dL.
- •Adequate renal function with creatinine =< 1.5 times upper limit of normal (ULN)
- •Adequate biliary function with bilirubin < 3.0 g/dL (including patients who have been bypassed or treated with percutaneous drainage), serum glutamic pyruvic transaminase (SGPT) (alanine transaminase) =< 2.5
- •Age > 18 years
- •Signed informed consent.
- •No known allergy to one of the study drugs
- •For female patient of childbearing potential, neither pregnant nor breastfeeding, and under active contraception
- •No prior malignancy within last 5 years
- •No central nervous system metastases
- •No peripheral neuropathy > grade2
- •No other serious concomitant illness
排除标准
- •Active infection or uncontrolled infection
- •Presence of metastatic disease.
- •Inadequate organ function as discussed above.
- •Pregnancy
- •Serious concomitant systemic disorder.
- •Use of any investigational agent within a month of treatment
研究组 & 干预措施
Oxaliplatin+ 5FU+ radiation (RT) /surgery /FOLFOX 6
Concurrent chemoradiation before surgery and FOLFOX6 regimen after surgery
Radiation (RT) 180cGy daily x 5 days/week x 5 weeks, then additional 540 cGy in 3 fractions over a half week to pancreatic portal;
Combined with :
5FU 200 mg/m^2 daily by continuous intravenous infusion (CIV) x 5 weeks and weekly Oxaliplatin 60 mg/m^2, IV for 5 weeks (in Phase I, 30, 40, 50, and 60 mg/m^2 Oxaliplatin were tested).
Observation for 2 weeks to assess dose-limiting toxicity (DLT)/Response. Surgery if deemed resectable.
Then modified FOLFOX 6 for 6 cycles (2 weeks/cycle):
Day 1 hour 0: Oxaliplatin 85 mg/m^2 intravenously (IV) + Leucovorin 350 mg IV over 2 hours; hour 2: 5FU 400 mg/m^2 IV bolus followed by 2400 mg/m^2 IV over 46 hours.
干预措施: Oxaliplatin (Drug)
Oxaliplatin+ 5FU+ radiation (RT) /surgery /FOLFOX 6
Concurrent chemoradiation before surgery and FOLFOX6 regimen after surgery
Radiation (RT) 180cGy daily x 5 days/week x 5 weeks, then additional 540 cGy in 3 fractions over a half week to pancreatic portal;
Combined with :
5FU 200 mg/m^2 daily by continuous intravenous infusion (CIV) x 5 weeks and weekly Oxaliplatin 60 mg/m^2, IV for 5 weeks (in Phase I, 30, 40, 50, and 60 mg/m^2 Oxaliplatin were tested).
Observation for 2 weeks to assess dose-limiting toxicity (DLT)/Response. Surgery if deemed resectable.
Then modified FOLFOX 6 for 6 cycles (2 weeks/cycle):
Day 1 hour 0: Oxaliplatin 85 mg/m^2 intravenously (IV) + Leucovorin 350 mg IV over 2 hours; hour 2: 5FU 400 mg/m^2 IV bolus followed by 2400 mg/m^2 IV over 46 hours.
干预措施: 5FU (Drug)
Oxaliplatin+ 5FU+ radiation (RT) /surgery /FOLFOX 6
Concurrent chemoradiation before surgery and FOLFOX6 regimen after surgery
Radiation (RT) 180cGy daily x 5 days/week x 5 weeks, then additional 540 cGy in 3 fractions over a half week to pancreatic portal;
Combined with :
5FU 200 mg/m^2 daily by continuous intravenous infusion (CIV) x 5 weeks and weekly Oxaliplatin 60 mg/m^2, IV for 5 weeks (in Phase I, 30, 40, 50, and 60 mg/m^2 Oxaliplatin were tested).
Observation for 2 weeks to assess dose-limiting toxicity (DLT)/Response. Surgery if deemed resectable.
Then modified FOLFOX 6 for 6 cycles (2 weeks/cycle):
Day 1 hour 0: Oxaliplatin 85 mg/m^2 intravenously (IV) + Leucovorin 350 mg IV over 2 hours; hour 2: 5FU 400 mg/m^2 IV bolus followed by 2400 mg/m^2 IV over 46 hours.
干预措施: Radiation (Radiation)
Oxaliplatin+ 5FU+ radiation (RT) /surgery /FOLFOX 6
Concurrent chemoradiation before surgery and FOLFOX6 regimen after surgery
Radiation (RT) 180cGy daily x 5 days/week x 5 weeks, then additional 540 cGy in 3 fractions over a half week to pancreatic portal;
Combined with :
5FU 200 mg/m^2 daily by continuous intravenous infusion (CIV) x 5 weeks and weekly Oxaliplatin 60 mg/m^2, IV for 5 weeks (in Phase I, 30, 40, 50, and 60 mg/m^2 Oxaliplatin were tested).
Observation for 2 weeks to assess dose-limiting toxicity (DLT)/Response. Surgery if deemed resectable.
Then modified FOLFOX 6 for 6 cycles (2 weeks/cycle):
Day 1 hour 0: Oxaliplatin 85 mg/m^2 intravenously (IV) + Leucovorin 350 mg IV over 2 hours; hour 2: 5FU 400 mg/m^2 IV bolus followed by 2400 mg/m^2 IV over 46 hours.
干预措施: Surgery (Procedure)
Oxaliplatin+ 5FU+ radiation (RT) /surgery /FOLFOX 6
Concurrent chemoradiation before surgery and FOLFOX6 regimen after surgery
Radiation (RT) 180cGy daily x 5 days/week x 5 weeks, then additional 540 cGy in 3 fractions over a half week to pancreatic portal;
Combined with :
5FU 200 mg/m^2 daily by continuous intravenous infusion (CIV) x 5 weeks and weekly Oxaliplatin 60 mg/m^2, IV for 5 weeks (in Phase I, 30, 40, 50, and 60 mg/m^2 Oxaliplatin were tested).
Observation for 2 weeks to assess dose-limiting toxicity (DLT)/Response. Surgery if deemed resectable.
Then modified FOLFOX 6 for 6 cycles (2 weeks/cycle):
Day 1 hour 0: Oxaliplatin 85 mg/m^2 intravenously (IV) + Leucovorin 350 mg IV over 2 hours; hour 2: 5FU 400 mg/m^2 IV bolus followed by 2400 mg/m^2 IV over 46 hours.
干预措施: FOLFOX 6 (Drug)
结局指标
主要结局
Resectability After Chemoradiation
时间窗: 7.5 weeks
This is the number of patients whose tumors are resectable after the combination treatment of 5FU, oxaliplatin, and radiation (RT).
次要结局
- Median Overall Survival(up to 10 years since the start of the study)